Reduced TFAM expression has also been linked to tumor progression in colorectal cancer [20], chemoresistance in ovarian carcinoma [21], invasion in melanoma [22], and metastatic potential in pancreatic ductal adenocarcinoma [23]. Here, TFAM is linked to ovarian carcinoma.